NIH Backs Alzheimer's Drug Development With Open Science Portal To Speed Development
"Though more than five million Americans suffer from Alzheimer’s disease, patients have scant options to prevent and treat this form of dementia. So how do you speed the process of getting drugs to market? The National Institutes of Health believes you begin by sharing scientific data. To that end, the NIH has launched the Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD) Target Discovery and Preclinical Validation Project. Under this initiative, teams of scientists working in far-flung labs will generate molecular and clinical data (genomic, epigenomic, RNAseq, proteomic) from more than 2,000 human brains. To enable the sharing of the resulting datasets, the NIH has funded the AMP-AD Knowledge Portal, an environment where massive amounts of data can be stored, accessed, and collaboratively analyzed ..."